Post-angioplasty Far Infrared Radiation Therapy Improves 1-Year Angioplasty-Free Hemodialysis Access Patency of Recurrent Obstructive Lesions

January 1, 2014

Abstract

Objective: To explore the role of far infrared (FIR) radiation therapy for hemodialysis (HD) access maintenance after percutaneous transluminal angioplasties (PTA).

Methods: This was a prospective observational study. Eligible patients were those who received repeated PTA with the last PTA successfully performed within 1 week before the study enrollments. Consecutively enrolled patients undergoing successful HD treatments after PTA were randomly assigned to the FIR-radiated group or control group without radiation. FIR-radiated therapy meaning 40-minute radiation at the major lesion site or anastomosed site three times a week was continued until an end-point defined as dysfunction-driven re-PTA or the study end was reached.

Results: Of 216 participants analyzed, including 97 with arteriovenous grafts (AVG) (49 FIR-radiated participants and 48 control participants) and 119 with arteriovenous fistulas (AVF) (69 FIR-radiated participants and 50 control participants), the FIR-radiated therapy compared with free-radiated usual therapy significantly enhanced PTA-unassisted patency at 1 year in the AVG subgroup (16.3% vs. 2.1%; p < .01), but not the AVF subgroup (25.0% vs. 18.4%; p ¼ .50), and this accounted for the overall improved patency rates (21.4% vs. 10.3%; p ¼ .02).

Conclusions: This study suggests FIR-radiated therapy improves PTA-unassisted patency in patients with AVG who have undergone previous PTA.

-Eur J Vasc Endovasc Surg. 2013 Dec;46(6):726-32.

Want to know more?



Contact us for more detail


Learn more
Questions to FIRAPY
November 28, 2025
FIRAPY Study Club will host its first international FIRAPY Forum on December 6, 2025 (Saturday), in conjunction with APCN × TSN 2025 in Taipei.
24th JSVMR
November 2, 2025
FIRAPY featured at the 24th JSVMR Annual Meeting with a special symposium by Prof. Higashi and two new research presentations, highlighting role in vascular care.
July 16, 2025
FIRAPY Medical Japan proudly participated in the 70th Annual Meeting of the Japanese Society for Dialysis Therapy (JSDT) , held in Osaka from June 27 to 29, 2025 . This year marked a major milestone for FIRAPY in Japan: a total of 11 FIRAPY-related research presentations were featured during the congress—showcasing growing academic interest in far-infrared therapy as a supportive, non-invasive treatment in dialysis care. represents a significant milestone in FIRAPY’s ongoing academic engagement in dialysis-related research.
More Posts